Neogen Chemicals Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/k67j6pp83nneq6bewpzf6pfb.pdf

Key Takeaways


Battery Materials: The Inflection Quarter

Harin Kanani: "it is a little bit too early for me to say exactly how much it will be"

The BuLi Chem Acquisition: A Unique Chemistry Platform

Harin Kanani: "So that is a combination which is very unique in the world and whenever we want to innovate for our customers, they simply love this idea, especially when they know lithium price is going to fluctuate."

Legacy Business: Divergence and Recovery Signals


Working Capital and Profitability: The Investment Phase


Raw Material Prices: Stabilization with Upside Risk


CAPEX and the Optionality to Slow Down

Harin Kanani: "We will keep watching both, how the international electrolyte salt approvals are progressing as well as how India electrolyte demand is developing. In India, mostly, we feel it is a demand issue depending on how well the Indian battery industry starts manufacturing cells. And if required we can slowdown and we can moderate our CAPEX accordingly."

Guidance & Commitments

CommitmentSpecificsTimeline
Battery materials plant inaugurationGreenfield facility using MUIS technologySecond half of FY2026
Lithium salts capacity expansionExpand to 2,500 metric tons per annumEnd of current financial year
Battery materials revenue FY25₹200–250 crore; electrolyte demand picks up when customer cell trials beginEnd of Q2 / early Q3 FY25
Battery materials revenue FY26Minimum ₹250–300 crore at full utilization, plus contribution from additional capacity coming onlineFY26
Legacy revenue scale₹1,000 crore-plus revenue from Neogen Chemicals, supported by current working capital baseFY26
Electrolyte salt customer approvalsTrial volumes shipping now; permissions expectedEnd of Q2 FY25
Electrolyte plant full utilizationDepends on how fast initial customers stabilize at even 1 GWh capacityQ4 FY25 or Q1 FY26
CAPEX moderation triggerSlow down or delay equipment/electrolyte module if approvals or domestic demand slipOngoing, watch through Q2/Q3 FY25
Working capital improvementSignificant reduction in days as utilization rises and new products are approvedOver the next 2 years

Key Metrics

MetricQ4 FY24
Consolidated revenue₹200 cr
Organic revenue growth22%
Inorganic revenue decline53%
Organic chemicals revenue₹169 cr
Inorganic chemicals revenue₹31 cr
EBITDA₹36 cr, +10% YoY
EBITDA margin18%
PAT₹17 cr, +18% YoY
FY24 consolidated revenue₹691 cr
FY24 EBITDA₹110 cr
FY24 EBITDA margin16%
FY24 PAT₹36 cr
FY24 organic chemicals revenue₹543 cr, +17% YoY
FY24 inorganic chemicals revenue₹148 cr
FY24 domestic/export mix73% / 27%
Consolidated net debt (FY24)₹381 cr, including current maturities of long-term debt
Final dividend recommended (FY24)₹2 per share, 20% of face value
Organic chemicals capacity utilization60%–65%
Inorganic chemicals capacity utilization75%–80%, close to full utilization
Organolithium revenue contribution₹17–18 cr
Volume growth, inorganic chemicals (Q4)4%–5% YoY
Volume growth, organic chemicals (FY24)25%–30%
Battery materials revenue readiness (FY25)₹200–250 cr
Battery materials minimum revenue target (FY26)₹250–300 cr
Total upcoming CAPEX (all sites)~₹1,500 cr
CAPEX expected in FY25₹400–500 cr, balance in FY26
Debt portion of ₹1,500 cr CAPEX~₹1,150 cr, funded by bankers
Lithium salts capacity commissioned200 MTPA of 400 MTPA plant, first approved material shipped
Lithium salts capacity expansion target2,500 MTPA by end of FY25
Electrolyte plant capacity2,000 MT, mechanical work complete, trial production commenced
India electrolyte demand estimate160 GWh, ~120 GWh EV, 30–40 GWh energy storage
Electrolyte salt as percentage of cell cost4%–5%
Electrolyte as percentage of cell cost8%–10%
Revenue breakup target by FY26 (non-battery)40% Bromine Derivatives, 20% CSM, 20% Advanced Intermediates, 15–20% non-battery lithium compounds
Current revenue breakup (non-battery)50–55% Bromine Derivatives, 30% Advanced Intermediates, 15–20% lithium chemicals
CCD infusion approved₹500 cr
Term loan tenure for Pakhajan site12 years, 2-year interest moratorium, 1-year principal moratorium, 9-year repayment
Government PLI subsidy as percentage of cell production cost25%–30%
U.S. import duty on electrolyte and components from China25%